NCT06626139View on ClinicalTrials.gov

Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 20, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2028

Conditions
Healthy Participants With Lower-than-average Mental Well-being
Interventions
DRUG

Psilocybin

Healthy participants will receive up to 25 mg psilocybin.

BEHAVIORAL

Context 1

Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.

BEHAVIORAL

Context 2

Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.

DRUG

Placebo

Healthy participants will receive an inactive placebo.

Trial Locations (1)

94158

RECRUITING

UCSF Mission Bay, San Francisco

All Listed Sponsors
lead

Robin Carhart-Harris, PhD, MA

OTHER